Wondfo Receives Health Canada Authorization for distribution of SAFElife™ Fentanyl Urine Home Test

Rapid and sensitive At-Home screening for Fentanyl in urine specimens

In our continued drive to provide our customers with innovative products that support the challenges of drug abuse our SAFElife™ Fentanyl Urine Home Test was granted Health Canada authorization for Canadian distribution.

The test is designed for rapid, over-the-counter (home) use, for detection of fentanyl at a cutoff of 1ng/mL and, is available in Dip Card or Cassette format.

Fentanyl is 50 times more potent than heroin and 100 times more potent than morphine, posing a significant threat of harm to individuals who ingest it knowingly or unknowingly – alone or in combination with other drugs.  2mg of fentanyl which is 10 times less than the weight of a single grain of rice is considered a lethal dose to an average adult.

Fentanyl exhibits potent effects at low concentrations: as little as 1-2 ng/mL provides pain relief while, 10-20 ng/mL achieves surgical anaesthesia.  Levels exceeding 7 ng/mL can be fatal, especially with poly-substance use which highlights fentanyl’s low therapeutic range and the need for highly sensitive detection methods.

“The extension of our SAFElife™ portfolio to include a home test for fentanyl is part of our ongoing commitment to provide innovative solutions to support the fight against the fentanyl epidemic.”

— Wingly Zhan, Senior Manager – Wondfo CA

Download our flyer to learn more.  Read the full press release here.